Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 15;11(11):787–802. doi: 10.1302/2046-3758.1111.BJR-2022-0101.R1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Author(s) et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Fig. 1 — Morphological and physiochemical characterization of calcium sulphate/hydroxyapatite-vancomycin/gentamicin (CaS/HA-VAN/GEN) with or without rifamipicin (RIF). a) and b) Scanning electron microscopy (SEM) images showing surface characteristics and pore distribution of CaS/HA-VAN/GEN pellets with or without RIF. Hemispherical pellets casted using an elastic mould of 4.8 mm diameter are shown in inset of a) and b). c) and d) Fourier transform infrared spectroscopy (FTIR) spectra from: c) CaS/HA-VAN, pure RIF, or CaS/HA-VAN + RIF; and d) CaS/HA-GEN, pure RIF, or CaS/HA-GEN + RIF. e) and f) Injectability of tested CaS/HA-VAN/GEN composites with or without RIF. An independent-samples t-test was used to compare the injectability of CaS/HA having VAN/GEN alone or in combination with RIF. *p < 0.05, **p < 0.01, ***p < 0.001.